Mission Pharmacal subsidiary ProSolus Inc. said this week that it expanded its manufacturing capabilities and commercialization efforts for transdermal drug delivery technologies. The Miami-based company, which develops and manufactures transdermal and trans-mucosal drug delivery products, installed a 2nd transdermal production facility in Boerne, Texas. The new location has a larger production line than the Miami […]
Drug-Device Combinations
Mercator enrolls first patient in BTK vascular disease trial
Mercator MedSystems said today that the 1st patient was enrolled in its Tango clinical trial. The trial is evaluating Mercator’s Bullfrog micro-infusion device for the adventitial delivery of temsirolimus below the knee in patients with critical limb ischemia. The Tango trial is the 4th ongoing clinical trial using the Bullfrog device in below the knee applications […]
United Therapeutics misses estimates for Q1 rev, earnings
Shares in United Therapeutics (NSDQ:UTHR) fell today after the biotech company missed expectations on Wall Street with its 1st quarter results. The Silver Spring, Md.-based company posted profits of $178.6 million, or $3.89 per share, on sales of $370.5 million for the 3 months ended March 31, for bottom-line loss of -24% on sales growth of 0.4% compared […]
Reva plans $40m convertible note offering
Reva Medical (ASX:RVA) said yesterday that it’s planning a $40 million convertible note offering with several institutional and 1 undisclosed corporate investor to fund the company’s ongoing needs, including the clinical development of its Fantom sirolimus-eluting bioresorbable coronary scaffold. Upon issuance of the convertible notes, the company is slated to receive $32.5 in net cash […]
3M posts Street-beating Q1 results, updates full-year guidance
Shares in 3M (NYSE:MMM) rose today after the company met expectations on Wall Street with its 1st quarter results. The St. Paul, Minn.-based company posted profits of $1.32 billion, or $2.16 per share, on sales of $7.69 billion for the 3 months ended March 31, for bottom-line growth of 3.1% on sales growth of 3.8% compared with […]
Medtronic touts drug-coated balloon in peripheral artery disease patients
Medtronic (NYSE:MDT) touted data today for its In.Pact Admiral drug-coated balloon in 2 sub-analyses of peripheral artery disease patients in the company’s In.Pact Global Study. The data were presented at the 2017 Charing Cross Symposium in London. Researchers presented 1-year outcomes in patients with complex lesions, as well as outcomes in a subset of patients with […]
Nanoparticle vaccine triggers immune system to fight multiple cancer types
Researchers from the University of Texas Southwestern Medical Center have developed a nanoparticle vaccine immunotherapy that fights multiple cancer types, according to a preclinical study published in Nature Nanotechnology. The nanovaccine, which the team calls a 1st of its kind, is made up of tumor antigens inside of a synthetic polymer nanoparticle. Get the full story […]
Portal wins ISO certification for needle-free drug delivery device
Medical device start-up Portal Instruments said today that it won ISO 13485:2012 certification from the National Standards Authority of Ireland. The Cambridge, Mass.-based company is developing a hand-held, needle-free drug delivery device. The device can precisely administer high viscosity biologics directly through the skin using a collimated jet that is the size of a strand […]
Sanofi levels antitrust suit against Mylan over EpiPen device
Sanofi (NYSE:SNY) reportedly sued Mylan (NSDQ:MYL) today, accusing the company of illegally suppressing competition to the EpiPen device. The lawsuit filed in a New Jersey federal court alleges that Mylan’s conduct has cost Sanofi hundreds of millions of dollars in sales for its rival allergy treatment, Auvi-Q. Canonsburg, Penn.-based Mylan has found itself at the center of […]
Study: Sirtex’s microspheres improve quality of life, but don’t extend survival
Sirtex Medical (ASX:SRX) said today that it’s yttrium-90 resin microspheres did not extend survival significantly compared to Bayer’s sorafenib in a study of patients with hepatocellular carcinoma. Although the 459-patient trial did not meet its primary endpoint, the company reported that patients treated with its microspheres experienced less than half the number of severe, treatment-related […]
Becton Dickinson to acquire Bard in $24B deal
Becton Dickinson (NYSE:BDX) has inked an agreement with C. R. Bard (NYSE:BCR) to acquire the medtech company for $317.00 per Bard common share in cash and stock, valuing the deal at $24 billion. In announcing the deal yesterday, Franklin Lakes, N.J.-based BD said it plans to create a new segment within the company, BD Interventional, to […]